#cancer treatment

Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.

Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.

Older and immunocompromised people and those with underlying health conditions could benefit most from additional shots.

Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.

Powell had received treatment for multiple myeloma, which can lead to poorer response to COVID-19 vaccines.

In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.

The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.

Stivarga also improved survival in those with recurrent HCC after a liver transplant.

Targeting a protein called cyclin D1 may be beneficial in cancer treatment in the setting of obesity and Type 2 diabetes.

Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.

Between August 2018 and January 2019, the FDA doubled the number of liver cancer treatments.

Stella Armstrong’s journey to a healthier life wasn’t easy.

With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.

Twice as many patients were alive 18 months after starting treatment.

Recommendations now include multiple systemic medications in addition to surgery and local therapies.

Latest version of legislation to bypass FDA oversight must now to go back to the Senate.